What is the hypoglycemic effect of Trelagliptin?

Trelagliptin (Trelagliptin), as a DPP-4 inhibitor, has received widespread attention for its hypoglycemic effect in the treatment of diabetes. DPP-4 inhibitors effectively help regulate blood sugar levels by prolonging the activity of GLP-1 (glucagon-like peptide-1), thereby promoting insulin secretion and inhibiting glucagon secretion. The main advantage of trotagliptin is its long-term hypoglycemic effect, which is especially suitable for the treatment of patients with type 2 diabetes.

Compared with other conventional hypoglycemic drugs, the hypoglycemic effect of trotagliptin is mainly reflected in its outstanding role in lowering blood sugar after meals. Trelagliptin helps to rapidly promote insulin secretion after a meal by increasing GLP-1 levels, while inhibiting glucagon secretion when blood sugar levels are too high. This mechanism of action makes trolagliptin particularly outstanding in controlling postprandial blood sugar fluctuations, thereby effectively reducing the occurrence of postprandial hyperglycemia in diabetic patients.

In addition to controlling postprandial blood sugar, trotagliptin can also stabilize blood sugar levels throughout the day and reduce fasting blood sugar. Due to its unique mechanism of action, trotagliptin can not only improve blood sugar levels in the short term, but also maintain relatively stable blood sugar control during long-term use, helping to delay the occurrence of diabetic complications and improve patients' quality of life.

The hypoglycemic effect of trotagliptin is also very good when used in combination with other hypoglycemic drugs, especially when patients require multiple treatments to control blood sugar. When used in combination with metformin, sulfonylureas and other drugs, trotagliptin can enhance blood sugar control and reduce the frequency of postprandial hyperglycemia.

In clinical studies, trotagliptin has shown significant hypoglycemic effects, especially in patients with higher glycemic loads. Some studies have shown that trotagliptin can significantly reduce HbA1c (glycated hemoglobin) levels, which is a long-term assessment of blood sugar control in patients with diabetes.

Reference materials:https://en.wikipedia.org/wiki/Trelagliptin